This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deng, X. Articles by Friedman, E. Search for Related Content PubMed PubMed Citation Articles by Deng, X. Articles by Friedman, E.

The Kinase Mirk/Dyrk1B Mediates Cell Survival in Pancreatic Ductal Adenocarcinoma

Department of Pathology, Upstate Medical University, State University of New York, Syracuse, New York

Requests for reprints: Eileen A. Friedman, Pathology Department, Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210. Phone: 315-464-7138; Fax: 315-464-8419; E-mail: friedmae{at}upstate.edu.

Ductal adenocarcinoma of the pancreas is almost uniformly lethal as this cancer is invariably detected at an advanced stage and is resistant to treatment. The serine/threonine kinase Mirk/Dyrk1B has been shown to be antiapoptotic in rhabdomyosarcomas. We have now investigated whether Mirk might mediate survival in another cancer in which Mirk is widely expressed, pancreatic ductal adenocarcinoma. Mirk was an active kinase in each pancreatic cancer cell line where it was detected. Mirk knockdown by RNA interference (RNAi) reduced the clonogenicity of Panc1 pancreatic cancer cells 4-fold and decreased tumor cell number, showing that Mirk mediates survival in these cells. Mirk knockdown by synthetic duplex RNAis in Panc1, AsPc1, and SU86.86 pancreatic cancer cells induced apoptosis and enhanced the apoptosis induced by gemcitibine. Mirk knockdown did not increase the abundance or activation of Akt. However, four of five pancreatic carcinoma cell lines exhibited either elevated Mirk activity or elevated Akt activity, suggesting that pancreatic cancer cells primarily rely on Mirk or Akt for survival signaling. Mirk protein was detected by immunohistochemistry in 25 of 28 cases (89%) of pancreatic ductal adenocarcinoma, with elevated expression in 11 cases (39%). Increased expression of Mirk was seen in pancreatic carcinomas compared with primary cultures of normal ductal epithelium by serial analysis of gene expression and by immunohistochemistry. Thus, Mirk is a survival factor for pancreatic ductal adenocarcinoma. Because knockout of Mirk does not cause embryonic lethality, Mirk is not essential for normal cell growth and may represent a novel therapeutic target. (Cancer Res 2006; 66(8): 4149-58)

This article has been cited by other articles:

				X. Deng, D. Z. Ewton, and E. Friedman Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species Cancer Res., April 15, 2009; 69(8): 3317 - 3324. [Abstract] [Full Text] [PDF]

				O. Bogacheva, O. Bogachev, M. Menon, A. Dev, E. Houde, E. I. Valoret, H. M. Prosser, C. L. Creasy, S. J. Pickering, E. Grau, et al. DYRK3 Dual-specificity Kinase Attenuates Erythropoiesis during Anemia J. Biol. Chem., December 26, 2008; 283(52): 36665 - 36675. [Abstract] [Full Text] [PDF]

				K. Jin, S. Park, D. Z. Ewton, and E. Friedman The Survival Kinase Mirk/Dyrk1B Is a Downstream Effector of Oncogenic K-ras in Pancreatic Cancer Cancer Res., August 1, 2007; 67(15): 7247 - 7255. [Abstract] [Full Text] [PDF]

				R. Kuuselo, K. Savinainen, D. O. Azorsa, G. D. Basu, R. Karhu, S. Tuzmen, S. Mousses, and A. Kallioniemi Intersex-like (IXL) Is a Cell Survival Regulator in Pancreatic Cancer with 19q13 Amplification Cancer Res., March 1, 2007; 67(5): 1943 - 1949. [Abstract] [Full Text] [PDF]